VOR Vor Biopharma Inc.

Overview and Growth

Vor Biopharma Inc. recorded fiscal 2025 net loss of $695.98M. Diluted earnings per share were -$70.50, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 9.87M, linking total earnings with the per-share result received by shareholders. The diluted share count was 187.3% higher than fiscal 2024, when diluted shares averaged 3.44M, adding context to the EPS comparison. At period end, total assets were $464.13M, framing the scale of the company’s operating and financing commitments.

Profitability

The company recorded an operating loss of $371.64M after the reported operating expense base. After all below-operating-line items, the company recorded a net loss of $695.98M for the fiscal year. EBITDA was negative $368.75M, showing a deficit before interest, taxes, depreciation, and amortization. The loss-to-assets relationship was 150.0%, placing the bottom-line deficit against the company’s resource base. The bottom-line deficit increased from $116.91M in fiscal 2024 to $695.98M.

Liquidity and Capital Structure

At period end, the $464.13M asset base was financed through $628.44M of liabilities and -$164.31M of equity. Equity was negative at -$164.31M, meaning liabilities exceeded the residual book value available to shareholders and weakening balance-sheet resilience. At period end, current assets of $458.11M compared with current liabilities of $25.17M, defining the company’s short-term resource position. The current ratio was 18.2x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Reported cash and equivalents were $396.49M, separating immediately recognizable cash resources from the rest of the current-asset base. Book equity represented -35.4% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 135.4% of total assets, quantifying the liability-funded share of the company’s resource base. Measured against total assets, cash and equivalents represented 85.4%, a balance-sheet composition measure rather than a liquidity forecast. Total assets were 224.8% higher than fiscal 2024 assets of $142.89M, measuring the company’s own balance-sheet change. Reported equity changed 270.0% from $96.66M in fiscal 2024, placing the current capital base lower year over year. The reported cash balance changed 383.8% from $81.95M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

Operating activities used $142.71M of cash, resulting in an operating cash outflow for the year. The company spent $941.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Operating cash flow and capital spending combined to leave a $143.65M cash deficit after capital spending. The free-cash-flow deficit equaled 31.0% of total assets, placing the cash shortfall against the company’s resource base. Cash absorbed by operations increased from $99.66M in fiscal 2024 to $142.71M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.